D-Street Buzz: Pharma stocks edge higher led by Aurobindo Pharma; Sun Pharma, Dr Reddy’s rise
BKM Industries | The company has sold 13,83,103 capital stock at BKM Industries through open market transactions, which reduces participation at 5.29 percent from 7.4 percent earlier.
The Securities Market of India was marketed on the morning of August 27, following the weaknesses of global signs in advance of the expected Jerome Powell discourse, later on the day at the Annual Economic Conference of Jackson Hole.
The Sensex was reduced 6.14 points or 0.01 percent to 55,942.96, and the ingenious had added 12.80 points, or 0.08 percent, at 16649.70.
Between the sectors, the Pharma Index added more than one percentage led by Aurobindo Pharma and Sun Pharma, which added more than one percentage, followed by Dr. Reddy’s laboratories, Cadila Healthcare, Biocon, Divis Labs and Cipla.
Aurobindo Pharma Farma was focused after the company’s subsidiary received the approval of US Food and Drug Administration. UU (USFDA) for the injection of cyclophosphamide used in the treatment of cancer.
Its subsidiary Eugia Pharma Pharma specialties received an approval of 505 (b) (2) NDA from the US regulator for cyclophosphamide injection 500 mg / 2.5 ml and 1 g / 5 ml vials, said a press release.
Although the Q1FY22 numbers of the pharmaceutical sector were largely online with expectations, they failed to encourage the market, since there was any growth, pressure related to the margin.
“Expectations were high in terms of winning, but most of the profits were online or the estimates were lost. The main problem for most pharmaceutical companies was the commentary on the concern about the price pressure in its American business, “said Santosh Meena, head of research, Swastika Investmart.
Anand Rathi brokerage firm Share and stock brokers expect the challenges most related to growth and margin persist in Q2FY22.
“We hope that the sales of the companies that we cover to grow 12.3 percent / 13.3 percent in fiscal year / FY23, driven by the growth of growth in the domestic market and launched in the US. UU, While EBITDA and PAT can cultivate 6.7 percent / 20.3 percent and 4 percent / 4 percent / 4 percent / 23 percent in FY22 / FY23, “said Anand Rathi.
